Erlocent Tablet 150 mg contains Erlotinib, a targeted anticancer medication belonging to the class of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. It is primarily used in the treatment of specific types of cancers where abnormal EGFR signaling promotes uncontrolled cell growth. Erlocent 150 mg works by inhibiting cancer cell proliferation, slowing disease progression, and improving clinical outcomes in eligible patients.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Erlocent Tablet 150 mg is indicated for the treatment of:

• Non-small cell lung cancer (NSCLC), particularly in patients with EGFR-activating mutations

• Locally advanced or metastatic pancreatic cancer, in combination with gemcitabine

• Advanced lung cancer after failure of at least one prior chemotherapy regimen, as directed by an oncologist

Therapeutic Class

• Antineoplastic agents

• EGFR Tyrosine Kinase Inhibitors

Pharmacology

Erlotinib selectively inhibits the tyrosine kinase activity of the epidermal growth factor receptor (EGFR), which is often overexpressed or mutated in certain cancers. By blocking EGFR-mediated signaling pathways, Erlocent 150 mg interferes with tumor cell proliferation, angiogenesis, invasion, and metastasis. This targeted mechanism allows Erlotinib to act specifically on cancer cells while minimizing damage to normal cells.

Dosage and Administration

• Recommended dose: 150 mg once daily

• Erlocent Tablet should be taken at least 1 hour before or 2 hours after food

• Treatment should continue until disease progression or unacceptable toxicity occurs

Dose adjustments may be required based on patient tolerance, liver function, and the occurrence of adverse effects. Therapy should be initiated and supervised by a qualified oncologist.

Method of Administration

• Oral administration

• Swallow the tablet whole with water

• Do not crush, chew, or split the tablet

Drug Interactions

• Strong CYP3A4 inhibitors or inducers may alter Erlotinib levels

• Concomitant use with proton pump inhibitors or H2 blockers may reduce absorption

• Smoking can significantly reduce Erlotinib plasma concentrations

Contraindications

Erlocent Tablet 150 mg is contraindicated in patients with:

• Known hypersensitivity to Erlotinib or any component of the formulation

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Commonly reported side effects include:

• Dermatological: Rash, dry skin, itching

• Gastrointestinal: Diarrhea, nausea, vomiting, loss of appetite

• General: Fatigue, fever

• Others: Stomatitis, conjunctivitis, elevated liver enzymes

Most adverse effects are mild to moderate and manageable with appropriate supportive care.

Pregnancy and Lactation

• Pregnancy: Erlocent Tablet 150 mg may cause fetal harm. It should not be used during pregnancy unless absolutely necessary

• Lactation: Breastfeeding is not recommended during treatment due to potential risk to the infant

Precautions and Warnings

• Monitor liver function regularly during therapy

• Use with caution in patients with hepatic impairment

• Interstitial lung disease-like symptoms have been reported; treatment should be discontinued if suspected

• Adequate contraception is recommended during treatment

Overdose

There is limited experience with Erlotinib overdose. In case of suspected overdose, supportive treatment and close medical supervision are recommended.

Storage Conditions

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children